Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
952 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | active not recruiting | Phase 3 | 382 | Hoffmann-La RocheINDUSTRY | 32 | Jul 10, 2026 | clinicaltrials |
| NCT05048797 | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | active not recruiting | Phase 3 | 454 | AstraZenecaINDUSTRY | 20 | Jul 10, 2026 |
| clinicaltrials |
| NCT05327894 | Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21) | recruiting | Phase 3 | 160 | Princess Maxima Center for Pediatric OncologyOTHER | 24 | Jul 10, 2026 | clinicaltrials |
| NCT02319837 | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 17 | Jul 9, 2026 | clinicaltrials |
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | active not recruiting | Phase 3 | 327 | Geron CorporationINDUSTRY | 26 | Jul 8, 2026 | clinicaltrials |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma(EPCORE FL-1) | active not recruiting | Phase 3 | 549 | GenmabINDUSTRY | 30 | Jul 8, 2026 | clinicaltrials |
| NCT03528694 | Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer(POTOMAC) | active not recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 12 | Jul 7, 2026 | clinicaltrials |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O) | active not recruiting | Phase 3 | 1,407 | AstraZenecaINDUSTRY | 20 | Jul 7, 2026 | clinicaltrials |
| NCT04464226 | Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | active not recruiting | Phase 3 | 402 | BayerINDUSTRY | 39 | Jul 7, 2026 | clinicaltrials |
| NCT05794906 | A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies(ARASTEP) | active not recruiting | Phase 3 | 985 | BayerINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma(FIRST-308) | active not recruiting | Phase 3 | 200 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 13 | Jul 6, 2026 | clinicaltrials |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma(GOLSEEK-1) | active not recruiting | Phase 3 | 850 | CelgeneINDUSTRY | 38 | Jul 6, 2026 | clinicaltrials |
| NCT03081143 | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy(RAMIRIS) | completed | Phase 2 / Phase 3 | 429 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 3 | Jul 2, 2026 | clinicaltrials |
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jul 2, 2026 | clinicaltrials |
| NCT06558279 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis(ADAPT oculus) | active not recruiting | Phase 3 | 141 | argenxINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML(QuANTUM-WILD) | active not recruiting | Phase 3 | 700 | Daiichi SankyoINDUSTRY | 28 | Jul 2, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT03173248 | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation(AGILE) | active not recruiting | Phase 3 | 146 | Institut de Recherches Internationales ServierOTHER | 20 | Jun 29, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)(ESCALADE) | active not recruiting | Phase 3 | 611 | Acerta Pharma BVINDUSTRY | 23 | Jun 25, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | active not recruiting | Phase 3 | 1,170 | Daiichi SankyoINDUSTRY | 29 | Jun 23, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)(SaLuDo) | active not recruiting | Phase 3 | 469 | PharmaMarINDUSTRY | 12 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | active not recruiting | Phase 3 | 281 | Alexion Pharmaceuticals, Inc.INDUSTRY | 19 | Jun 17, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | active not recruiting | Phase 3 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 22 | Jun 17, 2026 | clinicaltrials |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study(PALLAS) | active not recruiting | Phase 3 | 5,796 | Alliance Foundation Trials, LLC.OTHER | 21 | Jun 15, 2026 | clinicaltrials |
| NCT03570892 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma(BELINDA) | completed | Phase 3 | 330 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT04833114 | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)(Pola-R-ICE) | completed | Phase 3 | 306 | GWT-TUD GmbHOTHER | 4 | Jun 10, 2026 | clinicaltrials |
| NCT04879368 | RegoNivo vs Standard of Care Chemotherapy in AGOC(INTEGRATEIIb) | completed | Phase 3 | 462 | Australasian Gastro-Intestinal Trials GroupNETWORK | 9 | Jun 10, 2026 | clinicaltrials |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(PSMAddition) | active not recruiting | Phase 3 | 1,140 | Novartis PharmaceuticalsINDUSTRY | 19 | Jun 8, 2026 | clinicaltrials |
| NCT05904119 | Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study(LEGATO) | recruiting | Phase 3 | 411 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jun 8, 2026 | clinicaltrials |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | terminated | Phase 3 | 358 | Novartis PharmaceuticalsINDUSTRY | 26 | Jun 4, 2026 | clinicaltrials |
| NCT04960709 | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin(VOLGA) | active not recruiting | Phase 3 | 712 | AstraZenecaINDUSTRY | 25 | Jun 4, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT04513925 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)(SKYSCRAPER-03) | completed | Phase 3 | 829 | Hoffmann-La RocheINDUSTRY | 26 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT04527991 | Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread(TROPiCS-04) | completed | Phase 3 | 711 | Gilead SciencesINDUSTRY | 27 | Jun 2, 2026 | clinicaltrials |
| NCT02231749 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | completed | Phase 3 | 1,096 | Bristol-Myers SquibbINDUSTRY | 28 | May 27, 2026 | clinicaltrials |
| NCT04980495 | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis(ADAPT NXT) | completed | Phase 3 | 69 | argenxINDUSTRY | 11 | May 27, 2026 | clinicaltrials |
| NCT05668988 | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | active not recruiting | Phase 3 | 324 | Dizal PharmaceuticalsINDUSTRY | 15 | May 26, 2026 | clinicaltrials |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)(EPCORE DLBCL-1) | active not recruiting | Phase 3 | 483 | GenmabINDUSTRY | 24 | May 22, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT04305470 | Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma(MEN-301) | completed | Phase 3 | 108 | NX Development CorpINDUSTRY | 3 | May 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials